Product News

Share this article:
Merck's overseas affiliate MSD said that Isentress (raltegravir) has been granted a license from the European Union Commission for use in combination with other antiretroviral medicinal products for the treatment of HIV-1 infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy. The FDA granted approval for Isentress in October.

Pfizer said it received an FDA approvable letter for dalbavancin HCl, its once-weekly two-dose antibiotic under review for treating adults with complicated skin and skin structure infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA).

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions